Search > Chronic Obstructive Pulmonary Disease
624 Participants NeededMy employer runs this trial

GSK5784283 for COPD

Recruiting at 1 trial location
Age: 18+
Sex: Any
Trial Phase: Phase 3
Sponsor: GlaxoSmithKline
Pivotal Trial (Near Approval)This treatment is in the last trial phase before FDA approval
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The study primarily aims to demonstrate the superiority of GSK5784283 as an add-on therapy compared to placebo in reducing the annualized rate of moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations.

Who Is on the Research Team?

GC

GSK Clinical Trials

Principal Investigator

GlaxoSmithKline

Are You a Good Fit for This Trial?

This trial is for men and women aged 40 to 80 who have moderate to very severe COPD with frequent flare-ups, higher symptom scores, and a specific blood marker (eosinophilic type). Participants must be current or former smokers already using inhaled COPD medications.

Inclusion Criteria

Elevated COPD assessment test (CAT) score
Current or former cigarette smokers
I am using triple or dual inhaled therapy for my COPD.
See 4 more

Exclusion Criteria

I have not had cancer in the past 5 years, except for certain skin or cervical cancers.
Other significant medical conditions impacting safety or study outcomes
I have had or plan to have lung volume reduction surgery or a valve procedure.
See 7 more

What Are the Treatments Tested in This Trial?

Interventions

  • GSK5784283

Trial Overview

The study compares the new drug GSK5784283 (Felcorekibart) plus usual COPD treatment against a placebo plus usual treatment. The goal is to see if adding GSK5784283 reduces how often patients have moderate or severe COPD flare-ups.

How Is the Trial Designed?

2

Treatment groups

Experimental Treatment

Placebo Group

Group I: Participants receiving GSK5784283 plus standard of careExperimental Treatment2 Interventions
Group II: Participants receiving matching placebo plus standard of carePlacebo Group2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

GlaxoSmithKline

Lead Sponsor

Trials
4,834
Recruited
8,389,000+
Headquarters
London, UK
Known For
Vaccines & Medicines
Top Products
**Advair (salmeterol, fluticasone propionate)**, **Shingrix (shingles vaccine)**, **Augmentin (amoxicillin/clavulanate potassium)**, **Ventolin (salbutamol sulfate)
Dame Emma Walmsley profile image

Dame Emma Walmsley

GlaxoSmithKline

Chief Executive Officer since 2017

MA in Classics and Modern Languages from Oxford University

Dr. Hal Barron profile image

Dr. Hal Barron

GlaxoSmithKline

Chief Medical Officer since 2018

MD from Harvard Medical School

Unbiased Results

We believe in providing patients with all the options.

Your Data Stays Your Data

We only share your information with the clinical trials you're trying to access.

Verified Trials Only

All of our trials are run by licensed doctors, researchers, and healthcare companies.